Navigation Links
Successful results against human leishmaniasis with a more efficient and economic vaccine
Date:12/19/2012

A research coordinated by the UAB has succeeded in testing a vaccine against leishmaniasis. The vaccine was tested with the best animal model existing, the golden hamster, and can be produced at low costs by using insect larvae. The research, published in the latest edition of PLoS ONE, is an important step towards the fight against a disease which causes the death of 70,000 people each year in developing countries and of countless dogs, which also suffer from this disease and are its natural reservoir.

Leishmaniasis is one of the main health problems existing at global scale. It is produced by the protozoan Leishmania infantum, and canines, which can also be infected with the disease, are the main reservoirs of the organism. The disease is transmitted by insects from the Phlebotominae subfamily (sandflies), which are very similar to mosquitos. Clinical manifestations can go anywhere from minor skin sores to organ complications and, in the worst cases, death. The disease causes 70,000 deaths a year, mainly in developing countries, and affects over 12 million people around the world. Some 1.5 to 2 million new cases appear each year and an additional 350 million people are at risk of contracting the disease. Leishmaniasis is considered an endemic disease in parts of Asia, Africa, southern Europe, Mexico, Central America and South America. With the AIDS epidemic, leishmaniasis in humans has reactivated in many countries. Current treatments are unsatisfactory and, even though the most reasonable via to fight the disease would be to obtain an efficient vaccine, conventional vaccines until now have failed.

The research team led by the UAB compared the results of applying different vaccine strategies to the best animal model in which to study the human variant of the disease: the golden hamster. The results show that the most effective strategy is a combination of two vaccines created by the researchers: three doses of DNA with genes from the L. infantum and two doses of proteins coded by these genes.

The protein vaccine can be obtained at a low cost thanks to the use of insect larvae. To create the vaccine scientists isolated protozoan genes, inserted them into a virus which affects insects (baculovirus) and used these to infect larvae of a small worm, the cabbage looper (Trichoplusia ni). The larvae act as bioreactors and produce in large amounts and at a much lower cost than conventional reactors based on microorganisms the proteins which code these genes, and which are responsible for a protective response in vaccinated individuals. Using this method, a DNA vaccine can be manufactured with the protozoan protein coding genes, and a second vaccine with proteins associated with these genes (produced at a low cost using insect larvae), with the aim of increasing its effectiveness. This vaccine strategy can be used both in a preventive and a therapeutic manner, in both humans and dogs. Presently, the possibility of a translational phase is being contemplated with the aim of transferring as quickly as possible the results of this basic research to clinical practices, and of increasing the efficacy even more by using drugs to boost the immune response.


'/>"/>
Contact: Maria Jesus Delgado
MariaJesus.Delgado@uab.cat
34-935-814-049
Universitat Autonoma de Barcelona
Source:Eurekalert

Related medicine news :

1. Dr. Farshchian: Muscular Contusions are Now Being Treated Successfully at The Center for Regenerative Medicine in Miami
2. QuickMedical Announces Successful Sales and Marketing Results for 2012
3. Muscular Contusions Are Now Being Treated Successfully by Dr. Farshchian Using Cell Therapy
4. Barrow researchers successfully destroy brain tumor cells
5. Imaging facility develops successful radiation dose reduction program
6. Study IDs 4 Key Habits of Successful Aging
7. Study: Clot removal devices successful tools for acute ischemic stroke treatment
8. New drug successfully halts fibrosis in animal model of liver disease
9. Health coaches could be key to successful weight loss, study suggests
10. DermaShoppe.com Celebrates Its Second Successful Year in Online Skin Care
11. Online weight loss programs that feature successful dieters may help
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... Ecocor ... Richard Pedranti Architect (RPA), a full-service architecture firm focusing on sustainable ... Solsken Line of Model Homes . Independently, Ecocor and RPA have extensive experience ...
(Date:9/22/2017)... ... September 22, 2017 , ... Pullano Law Offices, a ... L. Pullano has been selected to serve as President of the North Suburban ... the Installation and Award Dinner hosted by the NSBA at the North Shore Country ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... help you brush more effectively even on the go. Their electric toothbrushes aggressively ... and gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology with ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... Lyme and other tick-borne diseases through research, education and awareness, today announced the ... A noted immunologist and microbiologist, Dr. Sellati has more than 20 years of ...
(Date:9/21/2017)... ... 21, 2017 , ... The American Addiction Treatment Association (AATA) ... in the addiction treatment industry entitled: Special Investigations Unit (SIU) – What ... state and federal governments are increasingly scrutinizing the addiction treatment industry for fraudulent ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017  Medical ... knowledge and skills while treating their patients. ... hands-on experience without involving patients. Simulation provides ... Clinicians can carry out procedures, refine techniques ... risk. Integration of new technology, such as ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical stage ... Ideation and Behavior (ASIB), has been granted Fast Track status ... therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + ... pivotal trial of this sequential therapy targeting patients who are ... ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and ... DoseCheck solution. Scannerside DoseCheck is a third-party Vendor neutral ... CT scanners and allows compliance with current MITA standards. ... proprietary XR 29 DoseCheck solution is specifically designed to ... alerts of potential radiation doses over a predefined threshold. ...
Breaking Medicine Technology: